Novel Antiangiogenic/Cytotoxic Therapies for Advanced Breast Cancer.
Abstract
It is now well documented that angiogenesis is required for the growth of both primary and metastatic breast cancer. Hence, inhibition of tumor-associated blood vessel growth should be an effective means of treating this disease. Our laboratory has investigated the structure/function relationships of a potent angiogenic mediator, termed angiogenin (Ang). Several inhibitors of its functions have been produced by us and shown previously to possess antitumor activity in preclinical models against a range of human solid tumor types. On this basis we were awarded a grant from the Department of Defense to extend our studies to the treatment of breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1998
- Accession Number
- ADA358070
Entities
People
- James W. Fett
Organizations
- Harvard Medical School